When was ivermectin invented

Overview

Ivermectin is a groundbreaking antiparasitic medication that revolutionized the treatment of neglected tropical diseases. Originally developed in the 1970s, it emerged from research into soil-dwelling microorganisms with potent biological activity.

The drug has since become a cornerstone in global health efforts to eliminate diseases like river blindness and lymphatic filariasis. Its discovery marked a turning point in veterinary and human medicine, offering broad-spectrum efficacy with low toxicity.

• 1975: Japanese scientist Satoshi Ōmura isolated the bacterium Streptomyces avermitilis from a soil sample in Shizuoka, Japan.
• Merck & Co. collaboration: Ōmura sent bacterial cultures to Merck, where William C. Campbell identified the compound’s antiparasitic properties.
• 1981: Ivermectin was first licensed for veterinary use to treat parasites in livestock and pets.
• 1987: The World Health Organization approved ivermectin for human use, specifically targeting onchocerciasis (river blindness).
• Mass Drug Administration: Over 300 million people in more than 70 countries have received ivermectin through global health campaigns.

How It Works

Ivermectin targets invertebrate nervous systems, making it highly effective against parasitic worms and arthropods while remaining safe for mammals. It disrupts neural transmission by binding to glutamate-gated chloride channels, leading to paralysis and death of the parasite.

• Mechanism of Action: Ivermectin binds to glutamate-gated chloride channels in nerve and muscle cells, increasing permeability to chloride ions and causing hyperpolarization.
• Parasite Immobilization: This hyperpolarization leads to flaccid paralysis in nematodes and arthropods, preventing feeding and reproduction.
• Selective Toxicity: Mammals lack these specific channels in the central nervous system, giving ivermectin a high safety margin in humans and animals.
• Pharmacokinetics: After oral administration, peak plasma concentrations occur within 4 to 6 hours, with a half-life of about 12 to 18 hours.
• Dosing: A single oral dose of 150–200 mcg/kg is typically effective, with repeat dosing every 6–12 months in endemic areas.
• Metabolism: The liver metabolizes ivermectin via CYP3A4 enzymes, and it is excreted primarily in feces.

Comparison at a Glance

Below is a comparison of ivermectin with other common antiparasitic drugs across key metrics:

The table highlights ivermectin’s advantage in mass treatment programs due to its infrequent dosing and high safety profile. Unlike drugs requiring multi-day regimens, ivermectin’s single-dose strategy improves compliance and reduces logistical barriers in remote regions. Its integration into community-led distribution networks has been key to its global success.

Why It Matters

The invention of ivermectin has had profound humanitarian and economic impacts, particularly in low-resource settings. By targeting debilitating parasitic diseases, it has improved quality of life, reduced transmission, and supported economic development in endemic regions.

• Onchocerciasis control: Ivermectin has reduced transmission in 11 of 13 West African countries, moving them toward elimination.
• Lymphatic filariasis: Combined with albendazole, it has helped eliminate the disease in 15 countries since 2000.
• Cost-effectiveness: The drug costs less than $0.50 per dose, making it highly scalable in public health programs.
• Nobel recognition: Ōmura and Campbell received the 2015 Nobel Prize in Physiology or Medicine for their work.
• Animal health: Ivermectin protects livestock from mites, lice, and roundworms, boosting agricultural productivity.
• Pandemic misuse: Despite unproven claims, ivermectin was widely misused during the COVID-19 pandemic, highlighting the need for science communication.

Today, ivermectin remains one of the most impactful public health tools of the modern era. Its discovery exemplifies how natural product research can yield transformative therapies with global reach.